The Checkpoint Inhibitor Family
Humanized IgG4 Antibodies — PD-1/PD-L1/CTLA-4 Blockade and Structural SAR
## Overview
Immune checkpoint inhibitors (ICIs) have transformed oncology since ipilimumab's approval in 2011 and pembrolizumab/nivolumab's approvals in 2014. They are monoclonal antibodies that block inhibitory immune checkpoint receptors—CTLA-4, PD-1, or the PD-1 ligand PD-L1—thereby reinvigorating exhausted tumor-infiltrating T cells and enabling immune-mediated tumor destruction. While not "drugs" in the classical pharmacophore sense, their structural biology, antibody engineering decisions, and emerging small-molecule competitors constitute a rich SAR landscape with direct clinical consequences.
## The Checkpoint Biology
**CTLA-4** (CD152) is expressed on T cells and competes with CD28 for binding to B7-1 (CD80) and B7-2 (CD86) co-stimulatory molecules on antigen-presenting cells. CTLA-4 has higher affinity for CD80/CD86 than CD28; its upregulation after T cell activation provides a braking mechanism on early T cell priming in lymph nodes. Blocking CTLA-4 with ipilimumab releases this early brake and amplifies T cell activation globally.
**PD-1** (CD279) is expressed on T cells, B cells, and NK cells. Its ligands PD-L1 (CD274, B7-H1) and PD-L2 are upregulated by tumor cells and stromal cells in the tumor microenvironment (TME) in response to IFN-γ. The PD-1/PD-L1 interaction delivers an inhibitory signal (via SHP-2 phosphatase recruitment to PD-1 ITSM) that suppresses TCR signaling and induces T cell exhaustion. This is the primary mechanism of tumor immune escape in most solid tumors.
## Antibody Engineering: IgG Subclass Choices
The IgG subclass choice is a critical "SAR" decision for checkpoint inhibitors. **IgG4** (pembrolizumab, nivolumab, durvalumab) has minimal Fc effector function (reduced ADCC, reduced CDC) because its Fc binds FcγRIII (CD16, the ADCC-mediating receptor) with ~30-fold lower affinity than IgG1. This is desirable for PD-1 antibodies—you do not want to kill the PD-1+ T cells you are trying to reinvigorate. **IgG1** (ipilimumab, avelumab) retains full ADCC and CDC. For ipilimumab (anti-CTLA-4), ADCC-mediated depletion of CTLA-4+ regulatory T cells (Tregs) within the tumor may contribute to anti-tumor efficacy beyond mere CTLA-4 blockade.
## Pembrolizumab vs Nivolumab: Manufacturing and Structure
Both are anti-PD-1 IgG4 antibodies with S228P Fc hinge stabilization. Nivolumab was developed from fully human variable regions (transgenic mice expressing human Ig genes). Pembrolizumab was humanized from a murine anti-PD-1 antibody by CDR grafting onto human frameworks with back-mutations. Both achieve picomolar Kd against PD-1 (~0.005 nM pembrolizumab; ~3 nM nivolumab) and show comparable clinical efficacy across tumor types, though their CDR sequences and epitopes on PD-1 differ subtly (pembrolizumab contacts the CC' loop; nivolumab contacts the FG and BC loops of PD-1).
## PD-L1 vs PD-1 Targeting: Clinical and Mechanistic Distinctions
Atezolizumab, durvalumab, and avelumab block PD-L1 rather than PD-1. Mechanistic advantages claimed for PD-L1 blockade include: (1) preserving PD-1/PD-L2 signaling (PD-L2 may provide organ-protective immune suppression); (2) disrupting PD-L1/CD80 co-inhibitory interaction (a PD-1-independent checkpoint); (3) allowing ADCC against PD-L1-overexpressing tumor cells (avelumab retains IgG1 Fc for this). In practice, clinical outcomes between PD-1 and PD-L1 targeting are broadly comparable within indications, with tumor histology and biomarker status driving selection.
## Small Molecule Checkpoint Inhibitors
The large size (~150 kDa) of therapeutic antibodies limits tumor penetration and prevents oral administration. Small-molecule PD-L1 inhibitors (BMS-986189, CA-170) have been extensively studied. The BMS compounds are macrocyclic peptides that act as PD-L1 dimerizers: they bind a hydrophobic groove on PD-L1 and induce head-to-tail homodimerization that buries the PD-1 binding surface. This unusual mechanism achieves potent PD-L1 blockade without requiring the full antibody paratope. However, the clinical efficacy of small molecules in this space has so far been modest compared with antibodies.
## Key Takeaways
- IgG4 is chosen for PD-1/PD-L1 antibodies to prevent ADCC killing of reinvigorated PD-1+ T cells; IgG1 is used for CTLA-4 to exploit Treg depletion
- S228P Fc hinge stabilization prevents IgG4 Fab-arm exchange (half-antibody formation in vivo)
- PD-L1 vs PD-1 targeting has mechanistic differences (PD-L1/CD80 disruption, PD-L2 preservation) but similar clinical outcomes
- Avelumab uniquely retains IgG1 Fc for ADCC against PD-L1+ tumor cells—a potential efficacy advantage in specific contexts
- Small-molecule PD-L1 dimerizers (BMS class) represent a pharmacophore approach to checkpoint blockade with oral potential but reduced clinical efficacy to date
구조-활성 관계 요약
Key SAR findings for the checkpoint inhibitor family:
- PD-1 antibodies (pembrolizumab, nivolumab) block the PD-1/PD-L1 interaction at PD-1's FG loop and C'D loop, which contact PD-L1's IgV domain; the paratope overlaps completely with the PD-L1 binding surface (~1,000 Ų BSA).
- IgG4 subclass is preferred for PD-1/PD-L1 inhibitors because IgG4 has minimal Fc effector function (reduced ADCC, CDC)—this prevents antibody-mediated killing of PD-1+ T cells that the drug is meant to reinvigorate.
- Nivolumab's S228P Fc mutation (EU numbering) stabilizes the IgG4 hinge to prevent half-antibody formation (Fab arm exchange), a known IgG4 instability; pembrolizumab uses a similar Fc-stabilized IgG4.
- CTLA-4 inhibitors (ipilimumab) use IgG1 (full ADCC/CDC capacity) because CTLA-4 is expressed on regulatory T cells (Tregs) in tumors—Fc-mediated depletion of intratumoral Tregs may contribute to efficacy.
- PD-L1 antibodies (atezolizumab, durvalumab, avelumab) offer a mechanistic distinction: blocking PD-L1 also prevents PD-L1/CD80 interaction, which has separate immune checkpoint signaling; avelumab retains IgG1 for ADCC against PD-L1+ tumor cells.
- Small-molecule PD-1/PD-L1 inhibitors (BMS-986189 class, macrocyclic peptides) act as PD-L1 dimerizers that sterically block PD-1 access; their smaller size enables tumor penetration advantages but weaker affinity vs antibodies.